101 related articles for article (PubMed ID: 34219681)
61. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Klanova M; Oestergaard MZ; Trněný M; Hiddemann W; Marcus R; Sehn LH; Vitolo U; Bazeos A; Goede V; Zeuner H; Knapp A; Sahin D; Spielewoy N; Bolen CR; Cardona A; Klein C; Venstrom JM; Nielsen T; Fingerle-Rowson G
Clin Cancer Res; 2019 Aug; 25(15):4634-4643. PubMed ID: 31053601
[TBL] [Abstract][Full Text] [Related]
62. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
63. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
Chen YB; Hochberg EP; Feng Y; Neuberg D; Rawal B; Motyckova G; Fisher DC; McAfee SL; Spitzer TR; Lacasce AS
Leuk Lymphoma; 2010 May; 51(5):789-96. PubMed ID: 20367136
[TBL] [Abstract][Full Text] [Related]
64. VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
Kaddu-Mulindwa D; Rosolowski M; Ziepert M; Regitz E; Assmann G; Bewarder M; Held G; Pfreundschuh M; Bittenbring JT
Eur J Haematol; 2021 Jan; 106(1):100-104. PubMed ID: 32997825
[TBL] [Abstract][Full Text] [Related]
65. Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.
Voropaeva EN; Voevoda MI; Pospelova TI; Maksimov VN
Br J Haematol; 2015 Apr; 169(1):32-5. PubMed ID: 25430047
[TBL] [Abstract][Full Text] [Related]
66. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
Rossi D; Rasi S; Franceschetti S; Capello D; Castelli A; De Paoli L; Ramponi A; Chiappella A; Pogliani EM; Vitolo U; Kwee I; Bertoni F; Conconi A; Gaidano G
Leukemia; 2009 Jun; 23(6):1118-26. PubMed ID: 19448608
[TBL] [Abstract][Full Text] [Related]
67. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
68. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ; Go H; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2014 Nov; 55(11):2466-76. PubMed ID: 24397616
[TBL] [Abstract][Full Text] [Related]
69. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
70. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
71. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.
Aviles A; Neri N; Nambo MJ
Am J Clin Oncol; 2012 Apr; 35(2):126-9. PubMed ID: 21325938
[TBL] [Abstract][Full Text] [Related]
72. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
[TBL] [Abstract][Full Text] [Related]
73. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
[TBL] [Abstract][Full Text] [Related]
74. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
[No Abstract] [Full Text] [Related]
75. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
76. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
77. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
[TBL] [Abstract][Full Text] [Related]
78. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
79. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
80. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]